INSM ▲ +0.2% - Insmed Incorporated $INSM INSM - Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 Insmed rose 0.2% today following an announcement that the company will present data from its respiratory portfolio at the European Respiratory Society Congress 2026, including new late-breaking results from a Phase 3b study of its ARIKAYCE treatment. The presentation of additional clinical data for a marketed respiratory therapy typically supports investor confidence in the drug's ongoing development and commercial potential. 03-SEP-2026 07:01 AM ET